PDGFRB (Ab-771) Antibody

What is PDGFRB and what is its role in cellular signaling pathways?

PDGFRB (Platelet-derived growth factor receptor beta) is a tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD, as well as for heterodimers formed by PDGFA and PDGFB. This receptor plays essential roles in:

• Embryonic development

• Cell proliferation, survival, and differentiation

• Chemotaxis and cell migration

• Blood vessel development (promoting proliferation, migration, and recruitment of pericytes and smooth muscle cells to endothelial cells)

• Formation of neointima at vascular injury sites

• Development of the cardiovascular system

The full-length protein has a molecular mass of approximately 123,968 daltons with two identified isoforms and contains sites of glycosylation . PDGFRB activation triggers several signaling cascades that regulate critical cellular functions, with the response depending on the nature and context of the stimuli .

How do PDGFR alpha and PDGFR beta differ in structure and function?

While PDGFR alpha (PDGFRα) and PDGFR beta (PDGFRβ) share structural similarities as receptor tyrosine kinases, they have distinct functional roles:

Recent research has revised the previous model of PDGF-PDGFR interactions, showing that PDGFRα can elicit circular dorsal ruffles (CDRs) and that PDGF-AB can robustly activate PDGFRβ homodimers, expanding its binding spectrum beyond previous understanding .

What factors affect antibody selection for PDGFRB detection?

When selecting a PDGFRB antibody for research, consider:

• Epitope specificity: Whether you need total PDGFRB or phosphorylation-specific detection (e.g., phospho-Y771, phospho-Y857, phospho-Tyr1009)

• Application compatibility: Validated applications (WB, IHC, ICC/IF, Flow cytometry, IP, ELISA)

• Species cross-reactivity: Human, mouse, rat, or other species specificity

• Clonality: Monoclonal antibodies offer higher specificity; polyclonal antibodies may provide stronger signals but with potential cross-reactivity

• Validation methods: Look for antibodies validated with knockout cell lines (e.g., PDGFRB knockout SH-SY5Y cells)

• Format: Unconjugated or conjugated (e.g., APC-conjugated for flow cytometry)

Research indicates significant variability in antibody performance - some widely used antibodies (e.g., sc-338 polyclonal) have shown non-specific binding in immunoblots and IHC, producing unreliable results compared to well-validated monoclonal antibodies (e.g., D13C6) .

What is the optimal protocol for detecting PDGFRB via Western blotting?

For optimal PDGFRB Western blot detection:

• Sample preparation:

  • Stimulate cells with appropriate PDGF ligands (e.g., PDGF-BB at 10-20 ng/ml for 10 minutes) after overnight serum starvation to enhance receptor activation

  • Lyse cells in buffer containing phosphatase inhibitors to preserve phosphorylation states

• Electrophoresis conditions:

  • Use reducing conditions with β-mercaptoethanol or DTT

  • Expect observed band size around 170-175 kDa (higher than the calculated 123 kDa due to post-translational modifications)

• Antibody application:

  • Primary antibody dilution typically 1:1000-1:10000 depending on antibody

  • For phospho-specific detection, use validated phospho-antibodies (e.g., p-Y771, p-Y857, p-Tyr1009)

  • Include controls: untreated vs. PDGF-stimulated samples

• Detection considerations:

  • High molecular weight smears may represent activated receptors rather than simple dimers or phosphorylation

  • The increase in signal in high-molecular weight regions correlates with increased phosphorylation

For phosphorylation-specific detection, research shows that the increase in signal in the high-molecular weight regions correlates well with increased phosphorylation detected by site-specific phospho-antibodies, regardless of which PDGF ligand is employed .

How should I optimize immunohistochemistry protocols for PDGFRB detection?

For optimal IHC detection of PDGFRB:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) or frozen sections

  • Cut sections at 4-5 μm thickness

• Antigen retrieval:

  • Heat-mediated antigen retrieval using Tris/EDTA buffer (pH 9.0) for 20 minutes at 97°C

  • Allow slides to cool to room temperature before proceeding

• Staining protocol:

  • Block endogenous peroxidases (e.g., with EnVision Flex Peroxidase Blocking Reagent for 5 min)

  • Apply primary antibody (concentration typically 1-2 μg/ml in antibody diluent) for 15-30 minutes

  • Use appropriate detection system (e.g., EnVision FLEX/HRP followed by DAB substrate)

  • Counterstain with hematoxylin, dehydrate, and coverslip

• Controls and validation:

  • Include positive control tissues (e.g., stromal cells in breast tissue for PDGFRB)

  • Include negative controls (omit primary antibody)

  • Consider including known positive and negative cell lines as controls

• Interpretation:

  • PDGFRB typically shows positive staining on stromal cells in tissues like breast and lung cancer

  • Evaluate membrane and cytoplasmic staining patterns

Research indicates that monoclonal antibodies like clone Y92 provide consistent and specific staining compared to polyclonal antibodies, which may show non-specific binding in IHC applications .

What strategies can be used to investigate PDGFRB activation by different ligands?

To study differential PDGFRB activation by various PDGF ligands:

• Receptor activation assays:

  • Stimulate cells with different PDGF ligands (PDGF-AA, PDGF-AB, PDGF-BB) at 20 ng/ml

  • Detect receptor activation via Western blot using phospho-specific antibodies

  • Monitor high molecular weight shifts that correlate with receptor activation

• Circular Dorsal Ruffle (CDR) formation assay:

  • Use phase contrast microscopy to visualize CDR formation after PDGF stimulation

  • Quantify the frequency of CDRs after treatment with various PDGF ligands

  • CDRs are visible after 3-6 minutes of stimulation in responsive cell lines

• Receptor-specific knockout approaches:

  • Generate PDGFR-deficient cell lines using CRISPR/Cas9 targeting different exons

  • Compare ligand responses in wild-type versus knockout cells

  • This approach helped reveal that PDGFRα can elicit CDRs, contrary to previous models

• Concentration-response studies:

  • Test varying concentrations of ligands (e.g., 10-100 ng/ml)

  • Generate concentration-response curves for different PDGF isoforms

  • Compare EC50 values to determine relative potencies

Recent research using these methodologies has challenged the accepted model by demonstrating that PDGF-AB can robustly activate PDGFRβ homodimers at 20 ng/ml, with activation levels approximately half that of PDGF-BB .

How is PDGFRB implicated in cancer biology and what are therapeutic approaches?

PDGFRB plays multiple roles in cancer biology:

• Tumor microenvironment:

  • Expressed by tumor-associated pericytes/smooth muscle cells

  • Present on cancer-associated fibroblasts and macrophages

  • Upregulated in the stroma of most solid tumors

• Cancer progression mechanisms:

  • Contributes to tumor angiogenesis

  • Promotes recruitment of pericytes to tumor vessels

  • Involved in migration of vascular smooth muscle cells

  • May regulate tumor fibroblasts and promote desmoplastic reactions

• Therapeutic approaches:

  • PDGFR antagonists in clinical development as antitumor agents

  • Fully human neutralizing antibodies (e.g., IMC-2C5) have shown promising preclinical activity

  • Combination strategies with anti-VEGFR2 antibodies show enhanced efficacy

  • Small molecule inhibitors (imatinib, sunitinib) target PDGFR signaling

Research shows that anti-PDGFRβ antibodies like IMC-2C5 significantly delay tumor growth in certain xenograft models (OVCAR-8, NCI-H460) but not others (OVCAR-5, Caki-1), suggesting context-dependent efficacy . Importantly, combinations of anti-PDGFRβ with anti-VEGFR2 antibodies demonstrated significantly enhanced antitumor activity compared to either agent alone .

What experimental models are best for studying PDGFRB function?

Several experimental models are suitable for investigating PDGFRB function:

• Cell line models:

  • NIH/3T3 fibroblasts: High endogenous PDGFRβ expression, commonly used for receptor activation studies

  • SH-SY5Y neuroblastoma cells: Express PDGFRβ, knockout lines available for validation

  • Tumor cell lines with varying PDGFRβ expression: NCI-H460, BxPC-3, OVCAR-8

  • Porcine Aortic Endothelial cells: Used for exogenous receptor expression in isolation

• Genetic models:

  • CRISPR/Cas9-mediated PDGFRB knockout cell lines

  • Patch mutant mouse-derived 3T3 fibroblasts (lacking PDGFRα)

  • Cell lines with targeted disruption of specific PDGFRβ exons

  • Note: Germline PDGFRα and β knockout mice are embryonic lethal

• Xenograft tumor models:

  • OVCAR-8 and NCI-H460: Responsive to anti-PDGFRβ therapy

  • BxPC-3, HCT-116: Show enhanced response to combination therapy

  • OVCAR-5 and Caki-1: Less responsive to PDGFRβ inhibition alone

• Assay readouts:

  • Circular Dorsal Ruffle (CDR) formation: Robust visual readout of early PDGFR signaling

  • Phosphorylation of specific tyrosine residues (Y771, Y857, Y1009)

  • Downstream pathway activation (MAPK, Akt)

  • Cell migration and proliferation assays

Recent genetic analyses in mouse fibroblast and melanoma cells using CDRs as a readout have successfully identified contradictory elements in the widely accepted model of PDGFR signaling .

How does PDGFRB interact with the VEGF signaling pathway in angiogenesis?

PDGFRB and VEGF signaling pathways interact in angiogenesis through several mechanisms:

• Complementary roles in vessel formation:

  • VEGF primarily targets endothelial cells to initiate vessel sprouting

  • PDGF-B/PDGFRβ signaling recruits pericytes and smooth muscle cells to stabilize vessels

  • This cooperation is essential for proper vessel maturation and function

• Compensatory mechanisms:

  • PDGF can induce downregulation of VEGFR-2 expression in endothelial cells

  • Anti-VEGFR2 therapy (e.g., DC101) elevates levels of VEGF and bFGF, which can be attenuated by anti-PDGFRβ antibodies (IMC-2C5)

• Therapeutic implications:

  • Combined inhibition of both pathways shows superior antitumor efficacy

  • In multiple xenograft models, combining anti-PDGFRβ antibody IMC-2C5 with anti-VEGFR2 antibody DC101 resulted in significantly enhanced antitumor activity

  • "Spectrum-selective" RTK inhibitors like sunitinib target both pathways and demonstrate good efficacy

• Molecular mechanisms:

  • PDGF-B is produced by endothelial cells and signals to PDGFRβ on pericytes

  • VEGF is produced by various cells including tumor cells and signals to VEGFR on endothelial cells

  • Pericytes provide survival signals to endothelial cells, maintaining vessel integrity

Research demonstrates that while imatinib (PDGFR-selective inhibitor) alone has limited efficacy in clinical trials, combined inhibition of VEGF and PDGF signaling causes tumor vessel regression by inducing endothelial cell apoptosis .

Why do I observe different molecular weight bands in PDGFRB Western blots?

Multiple bands in PDGFRB Western blots can occur for several reasons:

• Post-translational modifications:

  • Primary cause of the difference between calculated (123 kDa) and observed (170-175 kDa) molecular weight

  • Glycosylation significantly increases the apparent molecular weight

  • Phosphorylation states can alter migration patterns

• High molecular weight smears:

  • Often observed after ligand stimulation

  • Not likely receptor dimers (as blots are run under reducing conditions)

  • Cannot be explained by simple phosphorylation (phosphate groups too small to cause such large shifts)

  • Correlate with receptor activation status

• Proteolytic processing:

  • Receptor cleavage can generate fragments of different sizes

  • Processing may be cell-type specific or activation-dependent

• Antibody specificity issues:

  • Some antibodies (e.g., polyclonal sc-338) show multiple bands of unknown origin

  • Well-validated monoclonal antibodies (e.g., D13C6) typically show more specific banding patterns

• Isoforms:

  • PDGFRB has two identified isoforms that may appear as distinct bands

Research shows that in PDGFRα and PDGFRβ immunoblots, the increase in signal in high-molecular weight regions correlates well with increased phosphorylation detected by site-specific phospho-antibodies, regardless of which PDGF ligand is employed .

How can I validate the specificity of PDGFRB antibodies?

To validate PDGFRB antibody specificity:

• Knockout cell line validation:

  • Test antibodies on PDGFRB knockout cell lines (e.g., PDGFRB knockout SH-SY5Y cell line)

  • Compare with wild-type cells to confirm specific signal loss

  • A weak signal in knockout lines may represent cross-reactivity with PDGFRα

• Stimulation experiments:

  • Compare unstimulated vs. PDGF-stimulated samples

  • PDGF-BB should activate PDGFRβ while PDGF-AA typically does not

  • Observe expected phosphorylation or molecular weight shift changes

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide

  • Specific signals should be blocked by peptide competition

• Multiple application testing:

  • Confirm consistent detection across different applications (WB, IHC, IF)

  • Compare staining patterns with known expression profiles

• Comparison with other validated antibodies:

  • Test multiple antibodies targeting different epitopes

  • Consistent detection across different antibodies increases confidence

A systematic comparison between polyclonal antibody sc-338 and rabbit monoclonal antibody D13C6 revealed that sc-338 showed multiple bands of unknown origin on immunoblots, while D13C6 resulted in a prominent band at the expected molecular mass of PDGFRα. This suggests that sc-338 produces unreliable results and should not be used for IHC research grade assays .

What technical factors affect PDGF-induced activation of PDGFRB?

Several technical factors influence PDGF-induced PDGFRB activation experiments:

• Ligand selection and concentration:

  • PDGF-BB universally activates PDGFRβ (most efficient)

  • PDGF-AB activates PDGFRβ at approximately half the level of PDGF-BB

  • PDGF-AA generally doesn't appreciably activate PDGFRβ

  • Typical working concentrations: 10-20 ng/ml for robust activation

• Cell culture conditions:

  • Serum starvation (overnight) before stimulation enhances response

  • Cell density affects receptor expression and activation

  • Passage number can influence receptor expression levels

• Timing considerations:

  • PDGFRβ activation occurs rapidly (minutes)

  • CDR formation begins at 3-6 minutes post-stimulation

  • Receptor internalization and degradation follow activation

  • Time-course experiments are essential for capturing optimal activation

• Detection methods:

  • Phospho-specific antibodies (e.g., PDGFRβ Tyr751, Tyr771, Tyr1009) for direct activation measurement

  • High molecular weight shift correlates with activation status

  • Downstream signaling readouts (MAPK, Akt phosphorylation)

  • CDR formation as a visual readout (observed in 40-60% of responsive cells)

• Cell type dependencies:

  • Different cell types show varying receptor expression levels

  • PDGFR activation may depend on cross-talk between tumor cells and host microenvironment

  • Some cell lines may lack components of signaling pathways

Research has demonstrated that PDGF-BB elicits CDRs in approximately 40% of M28-D5 fibroblasts and 60% of 2054E melanoma cells, while PDGF-AB induces CDR formation at similar levels to PDGF-BB, contradicting the accepted model that only high concentrations of PDGF-AB can activate PDGFRβ homodimers .

How can PDGFRB antibodies be used to study receptor dimerization?

Investigating PDGFRB dimerization requires specialized approaches:

• Genetic approaches to isolate receptor subtypes:

  • Generate PDGFRα knockout cells to study PDGFRβ homodimers exclusively

  • Create PDGFRβ knockout cells to study PDGFRα signaling

  • This approach revealed that PDGF-AB can robustly activate PDGFRβ homodimers, contradicting previous models

• Ligand-specific stimulation:

  • PDGF-BB: Activates both PDGFRα and PDGFRβ homo- and heterodimers

  • PDGF-AB: Previously thought to preferentially activate PDGFRα homodimers and PDGFRα/β heterodimers, but now shown to also efficiently activate PDGFRβ homodimers

  • PDGF-AA: Primarily activates PDGFRα homodimers

• Biochemical approaches:

  • Immunoprecipitation with receptor-specific antibodies followed by immunoblotting

  • Cross-linking experiments to stabilize receptor dimers

  • Phosphorylation-specific detection to monitor activation states

• Functional readouts:

  • CDR formation as a visual indicator of receptor activation

  • Compare responses in wild-type versus receptor-specific knockout cells

  • Quantify frequency of CDRs after various ligand treatments

Research using these approaches has significantly revised our understanding of PDGF-PDGFR interactions: (1) PDGFRα can elicit CDRs, contradicting the assertion that PDGFRβ is solely responsible, and (2) PDGF-AB can robustly activate PDGFRβ homodimers, demonstrating a broader spectrum of efficient receptor binding than previously appreciated .

What are the emerging applications of anti-PDGFRB antibodies in cancer research?

Anti-PDGFRB antibodies are being applied in several innovative areas of cancer research:

• Targeting the tumor microenvironment:

  • Evidence suggests anti-PDGFRβ antibodies primarily affect PDGFRβ-expressing cells in tumor stroma rather than tumor cells directly

  • Targeting both cancer cells and their supporting (co-opted) cells enhances anticancer efficacy

• Combination therapy development:

  • Anti-PDGFRβ antibodies significantly enhance the antitumor and antiangiogenic activity of anti-VEGFR2 antibodies

  • Addition of anti-PDGFRβ to chemotherapy/anti-VEGFR2 combinations shows additive antitumor effects

  • These approaches have shown promise in multiple xenograft models (BxPC-3, NCI-H460, HCT-116)

• Biomarker development:

  • Anti-PDGFRβ antibodies help characterize PDGFRβ expression in tumor biopsies

  • This may identify patients more likely to respond to PDGFR-targeted therapies

  • Requires validated antibodies to avoid misleading results from non-specific antibodies

• Vessel normalization strategies:

  • PDGFRβ inhibition affects pericyte recruitment and vessel stability

  • When combined with anti-VEGF therapy, may promote vessel normalization

  • Could improve drug delivery and reduce tumor hypoxia

Research with the fully human neutralizing antibody IMC-2C5 demonstrates it binds both human and mouse PDGFRβ, blocks PDGF-B binding, inhibits ligand-stimulated activation, and significantly delays tumor growth in certain xenograft models .

How do post-translational modifications affect PDGFRB detection and function?

Post-translational modifications significantly impact PDGFRB detection and function:

• Glycosylation:

  • Major contributor to the difference between calculated (123 kDa) and observed (170-175 kDa) molecular weight

  • May affect antibody accessibility to epitopes

  • Influences receptor folding, stability, and cell surface expression

  • Can be cell-type and context dependent

• Phosphorylation:

  • Key indicator of receptor activation status

  • Different phosphorylation sites engage distinct downstream signaling pathways

  • Important sites include Tyr751, Tyr771, Tyr857, and Tyr1009

  • Requires phospho-specific antibodies for detection

• Ubiquitination:

  • Regulates receptor internalization and degradation

  • Affects receptor half-life and signaling duration

  • May create additional high molecular weight species in immunoblots

• Technical considerations for detection:

  • Sample preparation methods preserving phosphorylation (phosphatase inhibitors)

  • Reducing vs. non-reducing conditions for immunoblotting

  • Selection of appropriate antibodies recognizing modified forms

  • Use of deglycosylating enzymes to confirm glycosylation contribution to mobility shifts